HongShan-backed OnCusp Therapeutics snags $100m Series A

OnCusp Therapeutics has raised $100 million in a Series A funding round co-led by Novo Holdings, OrbiMed, and F-Prime Capital.

Related Keywords

Shanghai ,China ,Japan ,Zhongshan ,Jiangxi ,New York ,United States ,Japanese ,Chong Xu ,Eric Slosberg ,Daiichi Sankyo ,Diyong Xu ,Blackbird Bioventures ,Sandy Fu ,Karen Hong ,Marshall Wace ,Novo Holdings ,Cstone Pharmaceuticals ,Oncusp Therapeutics ,F Prime Capital ,Biotrack Capital ,Sofinnova Investments ,Catalio Capital Management ,Forge Life Science Partners ,Sequoia Capital China ,Oriza Seed Capital ,Bing Yuan ,